Related Experiment Videos

Angiotensin-converting-enzyme gene polymorphism and heart failure: a case-control study

L Covolo1, U Gelatti, M Metra

  • 1Department of Hygiene, University of Brescia, Brescia, Italy.

Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals
|November 7, 2003
PubMed

Insights

This study found no link between the angiotensin-converting enzyme (ACE) I/D gene variant and heart failure (HF) risk. Investigating ACE genotype in heart failure patients and controls revealed no significant association.

Area of Science:

  • Cardiovascular Medicine
  • Human Genetics
  • Molecular Biology

Background:

  • Heart failure (HF) is a significant public health concern and the end stage of many cardiovascular diseases.
  • The renin-angiotensin system is crucial in cardiovascular disease development.
  • The angiotensin-converting enzyme (ACE) I/D polymorphism is studied for its association with cardiovascular phenotypes due to its effect on serum ACE activity.

Purpose of the Study:

  • To investigate the association between the angiotensin-converting enzyme (ACE) I/D genotype and the risk of developing heart failure (HF).

Main Methods:

  • A case-control study was conducted with 229 HF patients (coronary heart disease or idiopathic dilated cardiomyopathy) and 230 controls.
  • Genotyping for the ACE I/D polymorphism was performed using a polymerase chain reaction (PCR) assay.

Main Results:

  • No statistically significant association was found between the ACE I/D genotype and heart failure (HF).

Conclusions:

  • The ACE I/D polymorphism does not appear to be a significant genetic risk factor for heart failure in the studied population.

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...